【Rohto Pharmaceutical】Conversion Price Adjustment for April 2026 | May 21, 2026

Overview of Capital Policy

Rohto Pharmaceutical approved a dividend of 25 yen per share for the fiscal year ending March 2026 at the Board of Directors meeting on May 21, 2026. As a result, the conversion price of the convertible bond-type convertible bonds with European yen denomination maturing in 2026, applicable from April 1, 2026, was adjusted. The conversion price before adjustment was 2,828.5 yen, but after adjustment, it became 2,817.2 yen. The reason for the adjustment is due to the dividend decision, following the provisions of the conversion price adjustment clause.

Impact on Shareholders and Future Outlook

The conversion price adjustment this time has changed the conversion conditions for existing convertible bonds into shares. The increase in dividends is considered part of shareholder returns, and future trends in dividend policies and capital policies are worth monitoring. The slightly lower post-adjustment conversion price may impact dilution risks and financial flexibility for fundraising.